Price targets

Analyst ratings

4 analysts rated this company in the past 90 days. The average target price is €22.75, this is a change of +71.6% compared to the current price.

• September 18, 2025

  Berenberg maintains Medios' 'Buy' rating - target 25 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Medios with a price target of €25. The attractive return on free cash flow and the valuation should offset the uncertainties caused by the changes in the pharmaceutical company's management, wrote Michael Heider in a study published Friday. The potential for a price target of around 70 percent is high./mf/stk

  Publication of the original study: September 18, 2025 / 4:30 p.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 14, 2025

  Hauck Aufhäuser IB maintains Medios at 'Buy' - target 22 euros

  HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its "Buy" rating for Medios following second-quarter results, with a price target of €22. The pharmaceutical manufacturer's cash from operating activities (free cash flow) lends upside potential to the valuation, wrote Alexander Galitsa in a study published Thursday. However, sales growth is still lacking momentum./rob/bek/nas

  Publication of the original study: August 14, 2025 / 7:36 a.m. / Time zone not specified in the study

  First distribution of the original study: August 14, 2025 / 8:21 a.m. / Time zone not specified in the study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 13, 2025

  Warburg Research maintains Medios' 'Buy' rating - target €26

  HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its "Buy" rating for Medios following second-quarter figures, with a price target of €26. The manufacturer of specialty pharmaceuticals has accelerated sales growth, wrote Thilo Kleibauer in a study released Thursday. The operating result (EBITDA) underpins the company's targets for the full year./rob/bek/mis

  Publication of the original study: August 13, 2025 / 11:15 a.m. / Time zone not specified in the study

  First distribution of the original study: Date not specified in the study / Time not specified in the study / Time zone not specified in the study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 14, 2025

  Deutsche Bank Research maintains Medios at 'Buy' - target 18 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Medios at "Buy" with a price target of €18 following the company's earnings release. The specialty pharmaceutical company had a solid first quarter, wrote Michael Kuhn in a study published Wednesday. However, the announced departure of the CEO has placed the company in a strategic transition phase./tih/edh

  Publication of the original study: May 14, 2025 / Time not specified in study / CET

  First distribution of the original study: May 14, 2025 / 7:53 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 10, 2025

  Hauck Aufhäuser IB maintains Medios at 'Buy' - target 22 euros

  HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its rating for Medios at "Buy" with a price target of €22. As a purely European-focused pharmaceutical company, Medios stands out as a rock in the face of tariff storms, wrote analyst Alexander Galitsa in a study released Friday. The defensive business model and free cash flow also support the value./mf/nas

  Publication of the original study: April 10, 2025 / 11:49 PM / CET

  First distribution of the original study: April 11, 2025 / 8:11 AM / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 1, 2025

  Warburg Research lowers target for Medios to 26 euros - 'Buy'

  HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has lowered its price target for Medios from €30 to €26, but maintained its "Buy" rating. The attractive free cash flow yield underpins his buy recommendation, wrote analyst Michael Heider in his commentary on the specialist for patient-specific therapies published on Tuesday./ag/tav

  Publication of the original study: April 1, 2025 / 8:15 a.m. / CET

  First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 25, 2025

  Warburg Research maintains Medios' 'Buy' rating - target 30 euros

  HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its rating for Medios at "Buy" with a price target of €30 following detailed annual figures. The pharmaceutical company's final key figures were consistent with the preliminary key data, wrote analyst Michael Heider in a study published Tuesday./edh/bek

  Publication of the original study: March 25, 2025 / 8:15 a.m. / CET

  First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 21, 2025

  Berenberg lowers target for Medios to 32 euros - 'Buy'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg lowered its price target for Medios from €35 to €32 ahead of detailed annual figures, but maintained its "Buy" rating. Analyst Sam England adjusted his forecasts for the pharmaceutical company to reflect the preliminary key figures and reduced his earnings estimates for 2025 and 2026. Overall, despite the ongoing pressure in the "old" business, 2024 was a year of transformation following the acquisition of Ceban Pharmaceuticals, he concluded on Friday. This puts Medios in a better position for further growth and margin increases in the medium term./edh/ag

  Publication of the original study: March 21, 2025 / 7:02 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 5, 2025

  Deutsche Bank Research maintains Medios at 'Buy' - target 18 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Medios at "Buy" with a price target of €18. The specialty pharmaceutical company's preliminary key figures for fiscal year 2024 were in line with expectations, wrote analyst Michael Kuhn in his commentary published on Wednesday./edh/ag

  Publication of the original study: March 5, 2025 / Time not specified in study / CET

  First distribution of the original study: March 5, 2025 / 7:58 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 6, 2025

  Warburg Research maintains Medios' 'Buy' rating - target 30 euros

  HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its rating for Medios at "Buy" with a price target of €30. The pharmaceutical company's acquisition of Ceban Pharmaceuticals will leverage synergies, wrote analyst Michael Heider in a study published Thursday. Ceban is a good fit for Medios and represents a first step toward internationalization./mf/mis

  Publication of the original study: February 6, 2025 / 8:15 a.m. / CET

  First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 29, 2025

  Berenberg maintains Medios' 'Buy' rating - target 35 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its rating for Medios at "Buy" with a price target of €35. Analyst Sam England wrote in a study published Thursday that 2024 was a transitional year for the specialty pharmaceutical company. The integration of Ceban remains an important aspect with a view to 2025./ajx/nas

  Publication of the original study: January 29, 2025 / 5:44 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 13, 2024

  Warburg Research lowers target for Medios to 30 euros - 'Buy'

  HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has lowered its price target for Medios from €36 to €30 and maintained its rating at "Buy." Despite all the setbacks, the specialty pharmaceutical company's shares remain attractive, analyst Michael Heider wrote in his assessment published Friday./ag/mis

  Publication of the original study: December 13, 2024 / 8:15 a.m. / CET

  First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 22, 2024

  Warburg Research maintains Medios at 'Buy' - target 36 euros

  HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its rating for Medios at "Buy" with a price target of €36. The internationalization strategy is bearing fruit, wrote analyst Michael Heider in his commentary on an investor event on Friday./ag/mis

  Publication of the original study: November 22, 2024 / 8:15 a.m. / CET

  First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 21, 2024

  Deutsche Bank Research lowers Medios target to 18 euros - 'Buy'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research lowered its price target for Medios from €23 to €18, but maintained its "Buy" rating. Revenue and profit growth were initially based solely on acquisitions, but their downsides were not adequately addressed in the reporting, wrote analyst Michael Kuhn in his review of the quarterly report published on Thursday. Organic trends were negative in the third quarter, but he also predicts a trend reversal in the fourth./ag/tih

  Publication of the original study: November 21, 2024 / Time not specified in the study / CET

  First distribution of the original study: November 21, 2024 / 7:50 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 13, 2024

  Warburg Research maintains Medios at 'Buy' - target 36 euros

  HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its rating for Medios at "Buy" after the company's earnings release, with a price target of €36. The third quarter brought a strong improvement in operating profitability, wrote analyst Michael Heider in a report published Wednesday. The integration of Ceban into the pharmaceutical company is also providing optimism./mf/mis

  Publication of the original study: November 13, 2024 / 8:15 a.m. / CET

  First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 13, 2024

  Berenberg maintains Medios' 'Buy' rating - target 35 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Medios following its quarterly results, with a price target of €35. Revenue missed the consensus estimate, analyst Sam England wrote in a report released Wednesday. The specialty pharmaceutical company's operating result (adjusted EBITDA) was in line with expectations. The expert therefore sees good progress in profit margins./edh/mis

  Publication of the original study: November 13, 2024 / 6:33 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 12, 2024

  Warburg Research maintains Medios at 'Buy' - target 36 euros

  HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its rating for Medios at "Buy" with a price target of €36. Analyst Michael Heider praised the strong increase in profitability on Tuesday following the quarterly report. The integration of Ceban, which has now fully materialized, confirms the trend at the end of the second quarter./ag/mis

  Publication of the original study: November 12, 2024 / 11:15 a.m. / CET

  First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 7, 2024

  Hauck Aufhäuser IB maintains Medios at 'Buy' - target 22 euros

  HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its "Buy" rating for Medios with a price target of €22. Analyst Alexander Galitsa noted encouraging feedback from a recent management roadshow in his commentary published on Monday. Accordingly, the specialty pharmaceutical company remains a promising growth opportunity, combined with strong cash flow./tih/ag

  Publication of the original study: October 7, 2024 / 8:05 a.m. / CEST

  First distribution of the original study: October 7, 2024 / 8:15 a.m. / CEST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 10, 2024

  Berenberg maintains Medios' 'Buy' rating - target 35 euros

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Medios with a price target of €35. Medical technology companies are back on track after a weak previous year, the experts wrote in their industry commentary published on Wednesday. Their favorites for the remainder of 2024 and into the new year are Fresenius, Alcon, and Biomerieux among the large caps. Among the small caps, they are focusing primarily on Advanced Medical Solutions, Hikma, and Stratec./ag/zb

  Publication of the original study: September 10, 2024 / 4:56 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.